It is made available under a CC-BY-NC-ND 4.0 International license .

1 Trends in antimicrobial resistance amongst Salmonella Typhi in Bangladesh: a 24-year

2 retrospective observational study (1999–2022)

- 3 Arif M Tanmoy,^{1,2} Yogesh Hooda,¹ Mohammad S I Sajib,¹ Hafizur Rahman,¹ Anik Sarkar,¹
- 4 Dipu Das,¹ Nazrul Islam,¹ Naito Kanon,¹ Md. Asadur Rahman,³ Denise O Garrett,⁴ Hubert P
- 5 Endtz,² Stephen P Luby,⁵ Mohammod Shahidullah,⁶ Md. Ruhul Amin,⁷ Jahangir Alam,⁷
- 6 Mohammed Hanif,⁷ Samir K Saha,^{1,8} and Senjuti Saha.^{1,*}
- 7
- ¹Child Health Research Foundation, Dhaka, Bangladesh.
- ⁹ ²Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, the

10 Netherlands.

- ³Popular Diagnostic Center, Dhaka, Bangladesh.
- ⁴Sabin Vaccine Institute, Washington, DC, USA.
- ⁵Division of Infectious Diseases and Geographic Medicine, Stanford University School of
- 14 Medicine, Stanford, California, USA.
- ⁶Department of Neonatology, Bangabandhu Sheikh Mujib Medical University, Dhaka,
- 16 Bangladesh.
- ⁷Department of Pediatrics, Bangladesh Institute of Child Health, Dhaka, Bangladesh.
- ⁸Department of Microbiology, Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh.

19

20 Short running title: Salmonella Typhi AMR Trends in Bangladesh (1999–2022).

It is made available under a CC-BY-NC-ND 4.0 International license .

21

- 22 *Corresponding author: Senjuti Saha, PhD; Child Health Research Foundation, Dhaka,
- 23 Bangladesh. Email: <u>senjutisaha@chrfbd.org</u>

It is made available under a CC-BY-NC-ND 4.0 International license .

25 Abstract

26	Background. Rising antimicrobial resistance (AMR) in Salmonella Typhi restricts typhoid					
27	treatment options, heightening concerns for pan-oral drug-resistant outbreaks. Bangladesh					
28	contemplates introducing typhoid conjugate vaccine (TCV) to address the typhoid burden and					
29	AMR. However, large-scale surveillance data on typhoid AMR in Bangladesh is scarce.					
30	Objective. This study explores the AMR trends in Salmonella Typhi isolates from Bangladesh,					
31	drawing comparisons with antibiotic consumption to optimize antibiotic stewardship strategies					
32	for the country.					
33	Methods. Our typhoid fever surveillance included two pediatric hospitals and three private					
34	clinics in Dhaka, Bangladesh, spanning 1999 to 2022. Blood cultures were performed at					
35	physicians' discretion; cases were confirmed by microbiological culture, serological, and					
36	biochemical tests. Antimicrobial susceptibility was determined following CLSI guidelines.					
37	National antibiotic consumption data for cotrimoxazole, ciprofloxacin, and azithromycin was					
38	obtained from IQVIA-MIDAS database for comparison.					
39	Results. Our 24-year surveillance, encompassing 12,435 Salmonella Typhi cases, revealed					
40	declining trends in first-line drugs (amoxicillin, chloramphenicol, cotrimoxazole) and multidrug					
41	resistance (MDR; 38% to 17%, 1999–2022). Cotrimoxazole consumption dropped, 0.8 to 0.1					
42	DDD/1000/day (1999–2020). Ciprofloxacin non-susceptibility persisted (>90%) with unchanged					
43	consumption (1.1-1.3 DDD/1000/day, 2002–2020). Low ceftriaxone resistance (<1%) was					
44	observed, with rising MIC (0.03 to 0.12 mg/L, 1999–2019). Azithromycin consumption					
45	increased (0.1 to 3.8 DDD/1000/day, 1999–2020), but resistance remained $\leq 4\%$.					

- 46 Conclusion. Our study highlights declining MDR amongst Salmonella Typhi in Bangladesh,
- 47 thus reintroducing first-line antimicrobials could work as an empirical treatment option for
- 48 typhoid fever. Our analysis provides a baseline for monitoring the impact of future interventions,
- 49 including the TCV, on typhoid burden and associated AMR.
- 50

It is made available under a CC-BY-NC-ND 4.0 International license .

51 Introduction

52 Antimicrobial resistance (AMR) poses a significant threat to public health, estimated to cause approximately 1.27 million deaths in 2019.¹ If unchecked, deaths linked to AMR infections 53 could multiply 10-fold by 2050 due to widespread antimicrobial use and a paucity of new 54 antimicrobials.^{2, 3} In response to this threat, multiple strategies have been proposed, ranging from 55 56 antibiotic stewardship to alternative antibiotic therapies. Implementing these interventions 57 requires guidance from surveillance data, but many low- and middle-income countries (LMICs) face substantial data deficits.¹ This study aims to provide insights into AMR trends in 58 Bangladesh for Salmonella enterica serovar Typhi (Salmonella Typhi), the etiological agent of 59 60 typhoid fever, over a 24-year period, from 1999 to 2022.

61

62 Typhoid fever is a pressing global public health concern, with the majority of cases occurring in South Asia.⁴ In Bangladesh, the typhoid burden is alarmingly high, especially in the capital city 63 of Dhaka, where the estimated incidence is 913 per 100,000 person-years.⁵ While the disease is 64 more prevalent among school-age children,⁶ those under 2 years old experience the highest 65 bacterial load.⁷ Clinical and epidemiological data on typhoid fever have been traditionally 66 67 reported from hospital-based surveillance studies, but, in many endemic countries, like 68 Bangladesh, a significant number of typhoid patients seek care at community-based diagnostic centers or, hospital outpatient departments (OPD).⁸⁻¹¹ This diverse care-seeking behavior 69 70 complicates the precise estimation of the disease burden and AMR trends for typhoid fever.

It is made available under a CC-BY-NC-ND 4.0 International license .

72	Management of typhoid fever is becoming increasingly difficult with rising AMR. Multi-drug					
73	resistant (MDR, defined as the concurrent resistance to amoxicillin, chloramphenicol, and co-					
74	trimoxazole) Salmonella Typhi isolates emerged in the 1970s. ^{12, 13} This led to ciprofloxacin as					
75	the primary treatment choice by mid-1980s, but resistance followed. By mid-2010s, over 90% of					
76	Salmonella Typhi in South Asia showed non-susceptibility to ciprofloxacin. ¹⁴ The current					
77	treatments include azithromycin and third-generation cephalosporins such as ceftriaxone, ¹³ but,					
78	reports of resistance to both drugs are increasing. ¹⁵⁻²⁰ The 2016 typhoid outbreak in Pakistan,					
79	caused by an extensively drug resistant (XDR; resistant to ceftriaxone, ciprofloxacin and first-					
80	line of antimicrobials) lineage, ¹⁹ sparked global concern. Additionally, a novel <i>acrB</i> -717 gene					
81	mutation linked to azithromycin resistance, ¹⁶ has narrowed treatment options and raised fears of					
82	a pan-oral drug-resistant (PoDR) outbreak. A recent pan-oral resistant typhoid case has been					
83	reported from Pakistan and required intravenous carbapenem and colistin treatment. ²¹ This					
84	highlights the looming threat of AMR and related financial burden on patients and healthcare					
85	systems which is struggling to cope with high typhoid prevalence in LMICs. ^{13, 22}					
86						
87	To curb this high burden of typhoid fever, the Government of Bangladesh is considering the					
88	introduction of a typhoid conjugate vaccine (TCV). Phase-III trials have showed that the vaccine					
89	reduces typhoid fever by 81-85% and it has been introduced in Pakistan, Liberia, Zimbabwe,					
90	Samoa, and Nepal. ^{23, 24} However, the continuous monitoring of AMR trends in the post-					
91	vaccination era is essential to ensure sustained support from policymakers. This is especially					
92	crucial for Bangladesh, which is poised to shed its Least-Developed Countries (LDC) status in					
93	2026 and start losing financial support from Gavi for vaccines. Amidst many competing					
94	priorities, policymakers of Bangladesh will require robust surveillance data to make informed					

95 decisions about the TCV program. To this end, our study provides insights on the historical

It is made available under a CC-BY-NC-ND 4.0 International license .

trends in AMR through a comprehensive typhoid surveillance dataset of 12,489 Salmonella

97 Typhi isolates, spanning 24 years (1999-2022). It elucidates correlations between AMR and

98 antibiotic consumption, providing a baseline to guide the design of antibiotic stewardship

99 policies. It also provides insights into designing empirical treatment strategies for typhoid fever

100 management and potential strategies to combat increasing AMR in Bangladesh.

101

Methods and Materials

103 Enteric fever surveillance

104 The Child Health Research Foundation (CHRF) has been conducting enteric fever surveillance in 105 Bangladesh since 1999, with a focus on the pediatric population (<18 years of age). This 106 surveillance is carried out at three sites in Dhaka, the capital of Bangladesh with the highest burden of typhoid fever.⁶ These sites are: (a) Bangladesh Shishu Hospital and Institute (BSHI), a 107 108 650-bed hospital that is the largest pediatric hospital in the country, (b) Dr. M R Khan Shishu 109 Hospital & Institute of Child Health (SSFH), a 250-bed hospital that is the second largest 110 pediatric hospital in Dhaka, and (c) three branches of the Popular Diagnostic Center (PDC), a 111 community-based consultation and diagnostic center. All cases were classified based on whether 112 they were treated in the outpatient facility (OPD) or admitted to the hospitals (in-patient, IPD). 113 All cases from PDC were classified as OPD. Blood samples were collected for microbiological 114 culture as a part of the diagnostic service at the attending physicians' discretion. BSHI and SSFH 115 are part of the Global Invasive Vaccine-Preventable Bacterial Disease Surveillance Network since 2009.²⁵ Details of all three sites and our enteric fever surveillance program have been 116 described previously.^{8, 26} All data used in this study are given in Supplementary Data S1. 117

It is made available under a CC-BY-NC-ND 4.0 International license .

118

119 Etiological confirmation and antimicrobial susceptibility testing

120 In all hospitals, routine blood cultures were performed using standard methods, as described earlier.^{8, 27} Salmonella Typhi isolates from PDC were reconfirmed at BSHI using biochemical 121 122 tests (Klingler's Iron agar, Simmons citrate agar, motility-indole, and urea agar tests) and 123 Salmonella agglutinating antisera (Thermo Scientific, MA, USA). Antibiotic susceptibility tests were conducted for amoxicillin, cotrimoxazole, chloramphenicol, ciprofloxacin, ceftriaxone, and 124 125 azithromycin using the Kirby-Bauer disc diffusion method (Oxoid, Thermo Scientific, MA, 126 USA). The minimum inhibitory concentrations (MICs) for ceftriaxone and ciprofloxacin were 127 determined for two subsets of isolates (from 1999–2019 and 1999–2016 respectively), using the broth microdilution method (Sigma-Aldrich, MO, USA).^{28, 29} All isolates collected before 2017 128 129 underwent MIC testing if recoverable on plates. Additionally, ceftriaxone MIC testing was 130 performed on a random set of isolates from the later period (2017–2019). Zone-diameters (ZD) 131 and MIC data were interpreted based on the guideline of Clinical and Laboratory Standards 132 Institute (CLSI), 2020. Azithromycin-resistant (ZD: <11 mm) and near-resistant (ZD: 11-13 mm) isolates were reconfirmed using Etest strips (bioMérieux, Marcy-l'Étoile, France). The MIC₅₀ for 133 134 ceftriaxone and ciprofloxacin, indicating the MIC value at which 50% of tested isolates could not 135 grow, was also calculated. Ceftriaxone MIC of two isolates (MIC >256 mg/L) were excluded from all related analyses, to mitigate the impact of outliers. 136

137

138 Acquisition and analyses of antibiotic consumption data

139 To compare the patterns of typhoid cases, we acquired antibiotic consumption data (1999-2020)

140 for co-trimoxazole, ciprofloxacin, and azithromycin from the IQVIA-Multinational Integrated

It is made available under a CC-BY-NC-ND 4.0 International license .

141 Data Analysis System (IQVIA-MIDAS®) database. This commercial database captures retail

- 142 pharmacy sales, encompassing the total antibiotic volumes sold to both retailers and hospital
- 143 pharmacies by wholesalers. It also records annual sales of each antimicrobial agent for each
- 144 country. We excluded antimicrobial sales data for the agricultural sector. Daily defined doses
- 145 (DDD) for these antimicrobials were gathered from ATC/DDD Index 2023
- 146 (<u>https://www.whocc.no/atc_ddd_index/</u>). DDD represents the assumed average maintenance
- 147 dose per day for its main indication in adults. Adjusting for population size, we calculated DDDs
- 148 per 1000 inhabitants per day, following the WHO's Global Antimicrobial Resistance and Use
- 149 Surveillance System (GLASS).³⁰ Annual population data for Bangladesh was collected from the
- 150 United Nations-World Population Prospect Report 2019.³¹
- 151

152 <u>Statistical analysis</u>

We used Pearson's correlation coefficients to assess correlations between yearly AMR patternsand consumption of co-trimoxazole, ciprofloxacin, and azithromycin. All correlation tests were

155 conducted in Stata v13.0. We also examined potential non-linear resistance patterns for

- 156 ciprofloxacin and ceftriaxone using their MIC data, and for azithromycin with yearly resistance
- 157 percentage data. The analyses for ciprofloxacin and ceftriaxone employed the generalized
- additive model (GAM) with the *mgcv* package in R (version R 4.2.3). The model formula was y
- 159 ~ s(x, bs = "cs"), with 3,214 and 3,518 observations for ciprofloxacin and ceftriaxone,
- 160 respectively. Yearly trend of azithromycin resistance was analyzed similarly in R (version R
- 161 4.2.3) using local polynomial regression.
- 162

It is made available under a CC-BY-NC-ND 4.0 International license .

163 **Results**

164 Resistance to the first-line antimicrobials amoxicillin, chloramphenicol, cotrim
--

- 165 Our typhoid fever surveillance recorded 12,435 *Salmonella* Typhi cases from 1999 to 2022 (Data
- 166 S1). Of these cases, 28% (3,478/12,435) required hospitalization (IPD) at either BSHI or SSFH
- 167 hospital (Figure S1). During this period, we observed a declining trend in resistance among
- 168 Salmonella Typhi isolates to the first-line antimicrobials—amoxicillin, chloramphenicol, and
- 169 cotrimoxazole. In 2002, resistance peaked at 80%, but decreased to less than 20% in recent years
- 170 for all three first-line antimicrobials (Figure 1a-c). This decline was also reflected in multidrug
- 171 resistance (MDR), which was 17% in 2022 (Figure 1d). The percentage of MDR isolates
- 172 remained \leq 26% since 2010 (average 20%; 18%–23% at 95% Confidence Interval, CI) and \leq 19%

173 since 2017 (average 17%; 15%–19% at 95% CI).

174

175 <u>Resistance to ciprofloxacin, ceftriaxone, and azithromycin</u>

176 Non-susceptibility to ciprofloxacin in *Salmonella* Typhi was notably high, reaching 95% in 2001

177 from 56% in 1999, and remained above 90% throughout the study period. In 2022, 98%

- 178 (1,266/1,298) of the isolates were non-susceptible to ciprofloxacin (Figure 2a). We further
- 179 examined the non-susceptibility trend to ciprofloxacin using minimum inhibitory concentration
- 180 (MIC) data (Figure 3a). Our analysis with the Generalized Additive Model (GAM) of the MIC
- 181 data revealed a consistent trend with no significant changes in non-susceptibility to
- 182 ciprofloxacin. The MIC trend for ciprofloxacin remained stable at approximately 0.25 mg/L
- 183 throughout the entire study period (Figure 3a).

It is made available under a CC-BY-NC-ND 4.0 International license .

185	Ceftriaxone resistance, on the other hand, was rare among Salmonella Typhi isolates during our					
186	study period. Only two isolates were ceftriaxone-resistant, one in 1999 and the other in 2000,					
187	with no further instances recorded (Figure 2b). To gain detailed insights into this resistance					
188	trend, we generated ceftriaxone MIC data for a subset of isolates $(n = 3,518)$ spanning from 1999					
189	to 2019. Our analysis showed a gradual increase in MIC values over time. Overall resistance to					
190	ceftriaxone rose from 0.03 mg/L in 2001 to 0.12 mg/L in 2019 (Figure 3b). While these values					
191	remained below the breakpoint for reduced susceptisbility (1.0 mg/L as per CLSI standards, red					
192	dashed line in Figure 3b), they represent a four-fold increase. A similar fourfold increase was					
193	observed in the ceftriaxone MIC_{50} during this period.					
194						
195	Azithromycin resistance in Salmonella Typhi was first identified in 2013 during our study period					
195 196	Azithromycin resistance in <i>Salmonella</i> Typhi was first identified in 2013 during our study period (Figure 2c). Subsequently, an average of 2% (1%–3%; 95% CI) of <i>Salmonella</i> Typhi isolates per					
196	(Figure 2c). Subsequently, an average of 2% (1%–3%; 95% CI) of <i>Salmonella</i> Typhi isolates per					
196 197	(Figure 2c). Subsequently, an average of 2% (1%–3%; 95% CI) of <i>Salmonella</i> Typhi isolates per year displayed resistance to azithromycin. An in-depth analysis using local polynomial					
196 197 198	(Figure 2c). Subsequently, an average of 2% (1%–3%; 95% CI) of <i>Salmonella</i> Typhi isolates per year displayed resistance to azithromycin. An in-depth analysis using local polynomial regression to examine the yearly percentage of azithromycin-resistant isolates did not show a					
196 197 198 199	(Figure 2c). Subsequently, an average of 2% (1%–3%; 95% CI) of <i>Salmonella</i> Typhi isolates per year displayed resistance to azithromycin. An in-depth analysis using local polynomial regression to examine the yearly percentage of azithromycin-resistant isolates did not show a substantial increase in azithromycin resistance since its initial identification in 2013 (no data					
196 197 198 199 200	(Figure 2c). Subsequently, an average of 2% (1%–3%; 95% CI) of <i>Salmonella</i> Typhi isolates per year displayed resistance to azithromycin. An in-depth analysis using local polynomial regression to examine the yearly percentage of azithromycin-resistant isolates did not show a substantial increase in azithromycin resistance since its initial identification in 2013 (no data					

- azithromycin with national antimicrobial consumption data (Figure 4). Cotrimoxazole
- 205 consumption exhibited a notable decline, from 0.8 defined daily doses (DDD) per 1,000 persons
- per day in 1999 to 0.1 DDD/1,000 persons/day in 2020 (Figure 4a). Concurrently, resistance to

It is made available under a CC-BY-NC-ND 4.0 International license .

cotrimoxazole showed a decreasing trend during this period (Figure 1c and 4a). Also, it showed significant correlation with consumption patterns (r = 0.77; p = 0.00 at a 95% confidence interval, CI).

210 Ciprofloxacin consumption remained consistent throughout the study period, between 1.1 and

211 1.6 DDD/1,000 persons/day (Figure 4b). Non-susceptibility to ciprofloxacin showed a stable

pattern as well, but no significant correlation with consumption was identified (r = 0.21; p = 0.38

at a 95% CI). On the other hand, azithromycin consumption increased by 38-fold during study

214 years, 1999-2020, from 0.1 DDD/1,000 persons/day to 3.8 DDD/1,000 persons/day. The average

annual increase in azithromycin consumption was 0.18 DDD/1,000 persons/day (0.07–0.29 at a

216 95% CI) (Figure 4c).

217

218 **Discussion**

219 This study provides a comprehensive analysis of 12,435 cases of typhoid fever cases spanning 24 220 years in Bangladesh, shedding light on AMR patterns of the disease. In endemic countries like 221 Bangladesh, typhoid fever is largely treated in the community settings while the hospitals deal 222 complicated cases. This unique care-seeking behavior made it challenging to estimate the true typhoid burden and extent of AMR.^{10, 11} In addition, hospital-based surveillance from 223 Bangladesh reported higher proportion of MDR typhoid cases than community settings,¹⁰ 224 225 potentially not reflecting the true scenario. To bridge this gap, we established a typhoid surveillance system in Dhaka, Bangladesh, covering both hospital and community sites.^{5, 8, 32, 33} 226 227 Popular Diagnostic Center (PDC), the community-based site and OPD of the two study hospitals 228 contributed 72% (8,957/12,435) of the cases in our study.

It is made available under a CC-BY-NC-ND 4.0 International license .

229

230	We analyzed the dataset to observe trends in AMR among Salmonella Typhi isolates over time.				
231	Notably, there were declining resistance patterns for first-line antimicrobials, including				
232	amoxicillin, chloramphenicol, and cotrimoxazole (Figure 1a-c). This decline was associated with				
233	a decrease in multidrug-resistant (MDR) typhoid cases (Figure 1d). Since 2017, over 80% of				
234	Salmonella Typhi isolates have remained susceptible to first-line drugs, with the average MDR				
235	rate during 2017–2022 being 17% (15%–19%, 95% CI). Similar reductions in MDR have been				
236	documented in enteric fever surveillances across various countries, including India, Vietnam,				
237	Laos, Indonesia, Nepal, and Pakistan (pre-2016 XDR outbreak). ³⁴⁻⁴¹ The Global Typhoid				
238	Genomics Consortium's report further supports decreasing MDR trends in several typhoid-				
239	endemic countries including Bangladesh, India, Nepal, Indonesia, and the Philippines. ⁴²				
240	Additionally, our data revealed a decreasing trend in cotrimoxazole consumption, a key first-line				
241	antimicrobial in Bangladesh (Figure 4a). It aligned with declining resistance to cotrimoxazole				
242	over time and demonstrated a significant correlation ($r = 0.77$; $p = 0.00$ at 95% CI; Figure 1c and				
243	4a). Further investigation is needed to understand the intricate relationship between drug				
244	consumption and resistance.				

245

Ciprofloxacin non-susceptibility and consumption, on the other hand, remained unchanged
(Figure 2a and 4b). The ciprofloxacin MIC also revealed continuing non-susceptibility (Figure
3a), indicating its ongoing ineffectiveness for treating typhoid in Bangladesh. The current
empirical typhoid treatment in the country is either ceftriaxone or oral azithromycin. Only two
ceftriaxone-resistant *Salmonella* Typhi isolates were identified in our study (in 1999 and 2000).
However, there was a gradual increase in ceftriaxone MIC from 0.03 to 0.12 mg/L over 20 years

It is made available under a CC-BY-NC-ND 4.0 International license .

(1999-2019; Figure 3b). Although still below the non-susceptibility breakpoint (1.0 mg/L as per
the CLSI⁴³), the ceftriaxone MIC may approach reduced susceptibility in the near future.

254

255	Azithromycin resistance in Salmonella Typhi was first identified in our study in 2013, but
256	remained sporadic with only 1% isolates in 2022 (Figure 2c). The consumption of the drug, on
257	the other hand increased by ~40-fold during 1999-2020 (Figure 4c). High azithromycin use may
258	exert selection pressure, potentially fostering both macrolide- and non-macrolide resistance
259	determinants in the gut. ⁴⁴ The underlying molecular cause of azithromycin resistance in
260	Salmonella Typhi is a single-point mutation in the AcrB efflux pump gene, acrB-717, reported
261	globally. ^{16, 42, 45} This mutation also independently emerged in diverse Salmonella Typhi
262	genotypes. ⁴⁵ Statistical modeling of a random Salmonella Typhi genome dataset from
263	Bangladesh suggests a rising effective population size of azithromycin-resistant isolates. ⁴⁶ Our
264	study findings do not demonstrate a similar trend (Figure 4c).
265	
266	The introduction of the typhoid conjugate vaccine (TCV) in Bangladesh has the potential to
267	markedly reduce typhoid burden, including drug-resistant cases. Once introduced, the expected
268	decreasing trend in the post-TCV period will facilitate the focused effort on effective
269	antimicrobial stewardship strategies for Bangladesh. Previous studies showed that for each
270	culture-confirmed typhoid case, at least three patients receive antibiotics in Bangladesh. ⁴⁷ The

271 TCV, with its decreasing trend, could significantly cut the antibiotic consumption in the country

which is historically high, even increasing according to our results (Figure 4b and 4c).

It is made available under a CC-BY-NC-ND 4.0 International license .

274 Before MDR typhoid spread across the globe, the first-line antimicrobials were widely used to 275 treat typhoid. These low-cost antimicrobial agents are well-tolerated and saved millions of lives from typhoid fever for decades (1950s–1980s).⁴⁸⁻⁵⁰ Even countries without MDR cases, like 276 Samoa island, continue using amoxicillin as the primary typhoid treatment,^{51, 52} emphasizing the 277 278 efficacy of these low-cost agents. The successful use of cotrimoxazole to treat typhoid in recent times, has also been reported.⁵³ All three first-line drugs have been listed as essential drugs by 279 the Government of Bangladesh since 1982, preventing pharmaceutical price hikes.⁵⁴ Unlike the 280 281 lengthy and expensive development of new antimicrobials, reintroducing these first-line drugs 282 for treating typhoid cases, requires no research investment. Instead, such step will provide a 283 crucial window for developing new classes of antimicrobial drugs, a process hindered by significant investment barriers in the last decade.⁵⁵ 284

285

286 However, reintroducing older drugs may raise concerns about the return of MDR with increased 287 use. The initial H58 Salmonella Typhi isolates in the 1990s carried MDR genes on an IncHI1 288 plasmid. Recent H58 Salmonella Typhi isolates in Bangladesh and other endemic countries have 289 integrated these MDR genes into a chromosomal island. This integration helps avoid plasmid-290 imposed fitness costs, which are negative impacts on bacterial reproduction and survival due to plasmid carriage.^{46, 56, 57} Due to these genomic changes, the re-emergence of MDR would require 291 292 this H58 lineage to become almost extinct (or at least <5%) before reconsideration. Continuous 293 clinical, laboratory, and genomic surveillance during post-TCV introduction is essential to secure a safe window for the use of the first-line of antimicrobials.⁴² Monitoring antimicrobial use and 294 295 resistance remains crucial for successfully treating typhoid and other infections effectively.

296

It is made available under a CC-BY-NC-ND 4.0 International license .

297	The results of our study should be considered within the context of several limitations. First, the
298	two hospitals participating in the surveillance were among the largest pediatric reference
299	hospitals in Bangladesh, resulting in a bias towards younger patients. Second, all study sites were
300	in Dhaka, which may not represent other parts of Bangladesh. However, our data reflect the high
301	typhoid burden in the Dhaka city with a reported 57% seropositivity for typhoid fever. ⁶ Third,
302	many typhoid patients in Bangladesh are empirically treated without blood culture confirmation.
303	No community-based enteric fever surveillance account for this, limiting comparisons. Finally,
304	national antibiotic consumption data from IQVIA-MIDAS® database were used in this study, as
305	regional or disease-specific data were unavailable.
306	
307	Taken together, our study describes the trends in antimicrobial resistance (AMR) amongst
308	Salmonella Typhi isolates in Bangladesh over the last two decades, correlating them with
309	antibiotic consumption. We proposed a potential antibiotic stewardship strategy, reintroducing
310	first-line antimicrobials for treating typhoid fever. Given their >80% susceptibility for all
311	Salmonella Typhi isolates since 2017, this strategy could offer a viable empirical treatment
312	option. Our analysis could serve as a crucial baseline for monitoring the impact of future
313	interventions, including the TCV and improvements in water, sanitation, and hygiene (WASH),
314	on typhoid burden and AMR in the country. The upcoming years are pivotal in combatting
315	typhoid fever, and our study will be instrumental in measuring the effectiveness of interventions
316	aimed at reducing the burden and AMR of this often-neglected tropical disease.
317	

317

It is made available under a CC-BY-NC-ND 4.0 International license .

318 Acknowledgment

- 319 We would like to thank all past and present members of the clinical microbiology and
- 320 epidemiology team of the Child Health Research Foundation.
- 321

322 Funding statement

- 323 The work presented here was supported by Gavi, the Vaccine Alliance, through the World
- 324 Health Organization-supported Invasive Bacterial Vaccine Preventable Diseases study (grant
- numbers 201588766, 201233523, 201022732, 200749550), by leveraging the Pneumococcal
- 326 Vaccines Accelerated Development and Introduction Plan (PneumoADIP), by the Bill and
- 327 Melinda Gates Foundation through SEAP (grant number INV-008335), and by the Child Health
- 328 Research Foundation (CHRF).
- 329

330 **Ethics statement**

All study protocols received approval from the Ethics Review Committees (ERC) of Bangladesh Shishu Hospital and Institute (BSHI). Informed written consent and clinical information were obtained from parents/legal guardians for hospitalized cases. For out-patient cases, no formal consent was obtained as blood samples were collected as part of routine clinical care at the discretion of the treating physician and data from routine clinical care were retrospectively included without identifiable information.

337

338 **Transparency declarations**

It is made available under a CC-BY-NC-ND 4.0 International license .

339 All authors declare no conflict of interest.

340

341 Data Availability Statement

342 All relevant study data are provided in the Supplementary Data S1 of the article.

343

344 **References**

- 1. Murray CJL, Ikuta KS, Sharara F et al. Global burden of bacterial antimicrobial resistance in
- 346 2019: a systematic analysis. *The Lancet* 2022; **399**: 629-55.
- 347 2. Atkins KE, Flasche S. Vaccination to reduce antimicrobial resistance. *The Lancet Global*348 *Health* 2018; **6**: e252.
- 349 3. Baker RE, Mahmud AS, Miller IF et al. Infectious disease in an era of global change. *Nature*
- 350 *Reviews Microbiology* 2021.
- 4. Stanaway JD, Reiner RC, Blacker BF et al. The global burden of typhoid and paratyphoid
- 352 fevers: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Infectious*
- 353 *Diseases* 2019.
- 354 5. Garrett DO, Longley AT, Aiemjoy K et al. Incidence of typhoid and paratyphoid fever in
- 355 Bangladesh, Nepal, and Pakistan: results of the Surveillance for Enteric Fever in Asia Project.
- 356 *The Lancet Global Health* 2022; **10**: e978-e88.
- 357 6. Aiemjoy K, Seidman JC, Saha S et al. Estimating typhoid incidence from community-based
- 358 serosurveys: a multicohort study. *The Lancet Microbe* 2022.
- 359 7. Saha SK, Baqui AH, Hanif M et al. Typhoid fever in Bangladesh: implications for vaccination
- 360 policy. *The Pediatric infectious disease journal* 2001; **20**: 521-4.
- 361 8. Saha S, Islam M, Saha S et al. Designing Comprehensive Public Health Surveillance for
- 362 Enteric Fever in Endemic Countries: Importance of Including Different Healthcare Facilities.
- 363 *The Journal of Infectious Diseases* 2018; **218**: S227-S31.
- 364 9. Marchello CS, Birkhold M, Crump JA. Complications and mortality of typhoid fever: A
- 365 global systematic review and meta-analysis. *Journal of Infection* 2020; **81**: 902-10.

- 10. Saha S, Saha S, Ruhulamin M et al. Decreasing trend of multiresistant *Salmonella* typhi in
- 367 Bangladesh. *The Journal of antimicrobial chemotherapy* 1997; **39**: 554-6.
- 368 11. Saha SK, Saha SK. Antibiotic resistance of *Salmonella* typhi in Bangladesh. *Journal of*
- 369 Antimicrobial Chemotherapy 1994; 33: 190-1.
- 12. Olarte J, Galindo E. Salmonella typhi resistant to Chloramphenicol, Ampicillin, and Other
- 371 Antimicrobial Agents: Strains Isolated During an Extensive Typhoid Fever Epidemic in Mexico.
- 372 Antimicrobial Agents and Chemotherapy 1973; 4: 597-601.
- 13. Saha SK, Tabassum N, Saha S. Typhoid Conjugate Vaccine: An Urgent Tool to Combat
- 374 Typhoid and Tackle Antimicrobial Resistance. *The Journal of Infectious Diseases* 2021; 224:
- 375 S788-S91.
- 14. Andrews JR, Qamar FN, Charles RC et al. Extensively Drug-Resistant Typhoid Are
- 377 Conjugate Vaccines Arriving Just in Time? New England Journal of Medicine 2018; 379: 1493-
- 378 5.
- 15. Djeghout B, Saha S, Sajib MSI et al. Ceftriaxone-resistant Salmonella Typhi carries an IncII-
- 380 ST31 plasmid encoding CTX-M-15. *Journal of medical microbiology* 2018; **67**: 620-7.
- 381 16. Hooda Y, Sajib MS, Rahman H et al. Molecular mechanism of azithromycin resistance
- among typhoidal *Salmonella* strains in Bangladesh identified through passive pediatric
- surveillance. *PLoS neglected tropical diseases* 2019; **13**.
- 17. Jacob JJ, Pragasam AK, Vasudevan K et al. *Salmonella* Typhi acquires diverse plasmids
- from other Enterobacteriaceae to develop cephalosporin resistance. *Genomics* 2021; **113**: 2171-6.
- 18. Sah R, Donovan S, Seth-Smith HMB et al. A novel lineage of ceftriaxone-resistant
- 387 Salmonella Typhi from India that is closely related to XDR S. Typhi found in Pakistan. Clinical
- 388 Infectious Diseases 2019.
- 389 19. Klemm EJ, Shakoor S, Page AJ et al. Emergence of an Extensively Drug-Resistant
- 390 *Salmonella enterica* Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding
- Resistance to Fluoroquinolones and Third-Generation Cephalosporins. *mBio* 2018; **9**: e00105-18.
- 392 20. Wong W, Rawahi HA, Patel S et al. The first Canadian pediatric case of extensively drug-
- 393 resistant Salmonella Typhi originating from an outbreak in Pakistan and its implication for
- apprict antimicrobial choices. *IDCases* 2019; **15**: e00492.
- 395 21. Nizamuddin S, Khan EA, Chattaway MA et al. Case of Carbapenem-Resistant Salmonella
- 396 Typhi Infection, Pakistan, 2022. *Emerging infectious diseases* 2023; **29**: 2395-7.

- 22. Levine MM, Simon R. The Gathering Storm: Is Untreatable Typhoid Fever on the Way?
- 398 *mBio* 2018; **9**: e00482-18.
- 399 23. Birkhold M, Mwisongo A, Pollard AJ et al. Typhoid Conjugate Vaccines: Advancing the
- 400 Research and Public Health Agendas. *The Journal of Infectious Diseases* 2021; **224**: S781-S7.
- 401 24. Carey ME, McCann NS, Gibani MM. Typhoid fever control in the 21st century: where are
- 402 we now? *Current Opinion in Infectious Diseases* 2022; **35**: 424-30.
- 403 25. Saha S, Saha SK. Invasive Bacterial Vaccine-Preventable Disease Surveillance: Successes
- 404 and Lessons Learned in Bangladesh for a Sustainable Path Forward. *The Journal of Infectious*
- 405 *Diseases* 2021; **224**: S293-S8.
- 406 26. Sajib MSI, Tanmoy AM, Hooda Y et al. Trends in antimicrobial resistance amongst
- 407 Salmonella Paratyphi A isolates in Bangladesh: 1999–2021. PLOS Neglected Tropical Diseases
- 408 2023; **17**: e0011723.
- 409 27. Saha SK, Naheed A, El Arifeen S et al. Surveillance for Invasive Streptococcus pneumoniae
- 410 Disease among Hospitalized Children in Bangladesh: Antimicrobial Susceptibility and Serotype
- 411 Distribution. *Clinical Infectious Diseases* 2009; **48**: S75-S81.
- 412 28. Tanmoy AM, Westeel E, De Bruyne K et al. *Salmonella enterica* serovar Typhi in
- 413 Bangladesh: Exploration of Genomic Diversity and Antimicrobial Resistance. *mBio* 2018; 9.
- 414 29. Andrews JM. Determination of minimum inhibitory concentrations. *Journal of Antimicrobial*
- 415 *Chemotherapy* 2001; **48**: 5-16.
- 416 30. WHO. GLASS manual on the management of antimicrobial consumption data. 2020.
- 417 31. UN. World Population Prospect Report 2019. World Population Prospects: Population
- 418 Division, Department of Economic and Social Affairs, United Nations, 2019.
- 419 32. Saha S, Islam M, Uddin MJ et al. Integration of enteric fever surveillance into the WHO-
- 420 coordinated Invasive Bacterial-Vaccine Preventable Diseases (IB-VPD) platform: A low cost
- 421 approach to track an increasingly important disease. *PLoS neglected tropical diseases* 2017; **11**.
- 422 33. Saha S, Islam MS, Sajib MSI et al. Epidemiology of Typhoid and Paratyphoid: Implications
- 423 for Vaccine Policy. *Clinical Infectious Diseases* 2019; **68**: S117-S23.
- 424 34. Balaji V, Kapil A, Shastri J et al. Longitudinal Typhoid Fever Trends in India from 2000 to
- 425 2015. *Am J Trop Med Hyg* 2018; **99**: 34-40.
- 426 35. Nga TVT, Duy PT, Lan NPH et al. The control of typhoid fever in Vietnam. Am J Trop Med
- 427 *Hyg* 2018; **99**: 72.

- 428 36. Roberts T, Rattanavong S, Phommasone K et al. Typhoid in Laos: an 18-year perspective.
- 429 Am J Trop Med Hyg 2020; **102**: 749.
- 430 37. Lugito NPH. Antimicrobial resistance of *Salmonella enterica* serovars Typhi and Paratyphi
- 431 isolates from a general hospital in Karawaci, Tangerang, Indonesia: A five-year review.
- 432 *International Journal of Microbiology* 2017; **2017**.
- 433 38. Jamilah J, Hatta M, Natzir R et al. Analysis of existence of multidrug-resistant H58 gene in
- 434 Salmonella enterica serovar Typhi isolated from typhoid fever patients in Makassar, Indonesia.
- 435 New Microbes and New Infections 2020; **38**: 100793.
- 436 39. Shrestha KL, Pant ND, Bhandari R et al. Re-emergence of the susceptibility of the
- 437 *Salmonella spp.* isolated from blood samples to conventional first line antibiotics. *Antimicrobial*
- 438 *Resistance & Infection Control* 2016; **5**: 22.
- 439 40. Khadka S, Shrestha B, Pokhrel A et al. Antimicrobial Resistance in *Salmonella* Typhi
- 440 Isolated From a Referral Hospital of Kathmandu, Nepal. *Microbiology Insights* 2021; 14:
- 441 11786361211056350.
- 442 41. Qamar FN, Yousafzai MT, Sultana S et al. A Retrospective Study of Laboratory-Based
- 443 Enteric Fever Surveillance, Pakistan, 2012–2014. *The Journal of Infectious Diseases* 2018; **218**:
- 444 S201-S5.
- 445 42. Carey ME, Dyson ZA, Ingle DJ et al. Global diversity and antimicrobial resistance of
- 446 typhoid fever pathogens: Insights from a meta-analysis of 13,000 *Salmonella* Typhi genomes.
- 447 *eLife* 2023; **12**: e85867.
- 448 43. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI
- supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute, 2020.
- 450 44. Doan T, Worden L, Hinterwirth A et al. Macrolide and Nonmacrolide Resistance with Mass
- 451 Azithromycin Distribution. *New England Journal of Medicine* 2020; **383**: 1941-50.
- 45. Sajib MSI, Tanmoy AM, Hooda Y et al. Tracking the Emergence of Azithromycin
- 453 Resistance in Multiple Genotypes of Typhoidal *Salmonella*. *mBio* 2021; **12**: e03481-20.
- 454 46. da Silva KE, Tanmoy AM, Pragasam AK et al. The international and intercontinental spread
- 455 and expansion of antimicrobial-resistant *Salmonella* Typhi: a genomic epidemiology study. *The*
- 456 *Lancet Microbe* 2022.
- 457 47. Andrews JR, Baker S, Marks F et al. Typhoid conjugate vaccines: a new tool in the fight
- 458 against antimicrobial resistance. *The Lancet Infectious Diseases* 2019; **19**: e26-e30.

- 459 48. Geddes AM, Murdoch JM. Ampicillin in the treatment of paratyphoid fever- a comparative
- 460 trial. *Postgrad Med J* 1964; **40**: 81-3.
- 461 49. Uwaydah M, Shamma'a M. The Treatment of Typhoid Fever with Ampicillin. *Lancet* 1964:
 1242-4.
- 463 50. Gilman RH, Terminel M, Levine MM et al. Comparison of Trimethoprim-Sulfamethoxazole
- 464 and AmoxiciIIin in Therapy of Chloramphenicol-Resistant and ChloramphenicolSensitive
- 465 Typhoid Fever. *Journal of Infectious Diseases* 1975; **132**: 630-6.
- 466 51. Sikorski MJ, Desai SN, Tupua S et al. Tenacious endemic typhoid fever in Samoa. *Clinical*
- 467 *Infectious Diseases* 2020; **71**: S120-S6.
- 468 52. Tanmoy AM. *Salmonella enterica* Serovar Typhi on an Island: No H58, No Multidrug
- 469 Resistance, but for How Long? *mBio* 2022; **13**: e02426-22.
- 470 53. Karki M, Pandit S, Baker S et al. Cotrimoxazole treats fluoroquinolone-resistant Salmonella
- 471 typhi H58 infection. *Case Reports* 2016; **2016**: bcr2016217223.
- 472 54. Directorate of Drug Administration. Report of the Expert Committee for Drugs on The
- 473 National Drug Policy of Bangladesh 1982. ed: Directorate of Drug Administration, Ministry of
- 474 Health & Population Control, Governement of the People's Repubvlic of Bangladesh., 1986;
- 475 page-7.
- 476 55. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to
- 477 bring a new medicine to market, 2009-2018. *Jama* 2020; **323**: 844-53.
- 478 56. Millan AS, MacLean RC. Fitness Costs of Plasmids: a Limit to Plasmid Transmission.
- 479 *Microbiology Spectrum* 2017; **5**: 10.1128/microbiolspec.mtbp-0016-2017.
- 480 57. Lima NCB, Tanmoy AM, Westeel E et al. Analysis of isolates from Bangladesh highlights
- 481 multiple ways to carry resistance genes in *Salmonella* Typhi. *BMC Genomics* 2019; **20**: 530.
- 482
- 483

It is made available under a CC-BY-NC-ND 4.0 International license .

484 Figure legends

- 485 Figure 1. Yearly trends in resistance (-R) and multidrug resistance (MDR) among Salmonella
- 486 Typhi Cases (1999-2022, Bangladesh). (a) Amoxicillin Resistance, (b) Chloramphenicol
- 487 Resistance, (c) Cotrimoxazole Resistance, and (d) MDR (defined as concurrent resistance to
- 488 amoxicillin, chloramphenicol, and cotrimoxazole). Information on MDR is presented for all

489 recorded cases.

490

- 491 Figure 2. Yearly trends in Salmonella Typhi susceptibility for Ciprofloxacin, Ceftriaxone, and
- 492 Azithromycin (1999-2022) in Bangladesh. (a) Ciprofloxacin Non-Susceptibility (NS), (b)
- 493 Ceftriaxone Resistance (-R), and (c) Azithromycin Resistance (-R). Susceptibility data were

494 present for 12,431, 12,414, and 8,187 cases respectively.

495

496 **Figure 3.** Changes in minimum inhibitory concentrations (MIC) for (a) ciprofloxacin and (b)

497 ceftriaxone among *Salmonella* Typhi cases from 1999 to 2022 in Bangladesh. The MICs were

determined for a total of 3,214 and 3,518 isolates for ciprofloxacin (1999–2016) and ceftriaxone

499 (1999–2019), respectively. The color of the dots represents resistant (red), intermediate (blue),

and susceptible (green) isolates. The generalized additive model (GAM) lines depict the changes

- in the MICs (black line), with a 95% confidence interval (grey shades) over time.
- 502
- 503 Figure 4. Patterns of antibiotic consumption and antimicrobial resistance in (a) Cotrimoxazole,
- 504 (b) Ciprofloxacin, and (c) Azithromycin among *Salmonella* Typhi Cases in Bangladesh from
- 505 1999 to 2020. Consumption data for ciprofloxacin was unavailable from 1999 to 2001.
- 506 Resistance (-R) or Non-susceptibility (NS) to cotrimoxazole, ciprofloxacin, and azithromycin are

It is made available under a CC-BY-NC-ND 4.0 International license .


507	presented on the	primary Y-axi	s. The secondar	v Y-axis displa	avs antibiotic	consumption.
507	presented on the	prinary r and	5. The secondar	y I anis displa	ays annoione	consumption,


represented as the Defined Daily Dose (DDD) per 1,000 persons per day (DDD/1,000 day/year).


509

510 Supplementary file legends

- 511 Figure S1. Overview of the *Salmonella* Typhi database of 12,435 cases collected from 1999–
- 512 2022 and MDR percentage in Bangladesh. Yearly hospitalized (IPD) and outpatient (OPD) case
- 513 numbers (on the left y-axis) are presented by the year of isolation. The x-axis labels indicate the
- number of isolates collected each year. Percentages of MDR for IPD and OPD cases per year
- 515 represented as lines on the right *y*-axis.
- 516
- 517 **Data S1.** Antimicrobial resistance dataset of 12,435 typhoid cases in Bangladesh from 1999 to
- 518 2022 (S=Susceptible, I=Intermediate, and R=Resistant).







proprint (internation by poor fortion) is the authorithmetical with a noonlos to de

